The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
about
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoDoxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenograftsPreclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyModulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic targetDR5 knockout mice are compromised in radiation-induced apoptosisBortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathwaysInhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomibThe TRAIL of oncogenes to apoptosis.Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cellsB lymphocytes are resistant to death receptor 5-induced apoptosis.Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.Regulation of apoptosis proteins in cancer cells by ubiquitin.Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.Emerging therapies in hematopoietic stem cell transplantationDifferential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicityNPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.TRAIL and its receptors as targets for cancer therapy.Polyamine metabolism in fungi with emphasis on phytopathogenic speciesTRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor developmentBone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsBortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewBortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
P2860
Q24650617-2C47208E-EF90-44F8-81E5-C9BB00E4201AQ24793079-2BEF7D86-2125-4F31-A415-56FE8F4FBE77Q24814325-8F44454C-223F-4138-8E40-46C210C8DE1AQ30544925-9E38E8AC-052A-4991-ADDC-A94C6FD3AEAEQ33388541-AC046017-7800-4DC8-9FCF-C19A9855A2EEQ33842215-D1397444-5DD4-4045-BFB5-3CE673975D67Q33861644-F6F96170-8C20-4FA4-A8D2-8AA519A02AB9Q33862527-FD931366-289D-4F0A-ACE3-A04A3E971312Q33907593-72A8053D-FE5C-4B2B-A2BC-33997CD0E3C6Q34332019-4FBA1B82-E809-4535-A3EA-79CFE88F99DBQ34354511-C9D0A630-0208-4220-B388-FA832A0EC4C8Q34384021-736B2870-9C13-41E7-ADDF-75AEE7246B1FQ34540808-2AEF0620-2B09-4A33-8705-F01D699FF207Q34541614-6E66EB11-D4E3-4A91-A7FF-F8DCF09EBA76Q34564468-F2A67371-300D-477D-90AC-152C99BE582BQ34605718-CC522806-265D-45AF-9C60-6BF04B07E3C5Q34728945-2A96A723-9969-43AC-AB19-811E744ECB56Q35070129-24AA6754-7DFB-4E4A-9FC1-986D50E7298FQ35082212-39E4374D-CACB-43E7-9214-75E0914A4EE5Q35089766-AE891AE7-B5E0-4386-8EC0-839CD84A6554Q35200982-B0FBE485-F3E2-461B-A523-249AF04C8DADQ35691538-B1F1ED26-3A3F-4FEA-AF08-219EB089B45AQ35762274-51F99D07-ED87-4BF3-BC41-C424A5D31557Q35825522-AA32E6A0-9AA1-4D31-AA05-FBF568CA5725Q35848453-83379126-EC4A-4B2B-B78A-D0CF73D963E3Q35850681-9C397569-8705-41A8-8C44-E9FD0A4821E8Q35915103-6BA0AD72-5919-4BFC-9EBC-751C8B71A49AQ35922585-1E9A9958-492B-4225-8A70-DFDDF7C2E104Q35927476-F780E4BE-A945-48B1-849E-89B5A3D01815Q36203991-F584566E-3CFC-4BB6-949F-4A5C29767ABBQ36249542-57E73F89-E955-41C1-A707-3C1C596A254BQ36251308-5FCC72EA-3CDC-4AB5-9955-6D971AB09882Q36292020-BBC97BFC-5131-4149-8FFD-F37F2BC19D88Q36347307-7607815F-2FE4-461D-94BF-5FFCDCFBB1C2Q36365504-61F730B8-B094-409D-BBAE-BEE2B8BE63FCQ36378038-2EF96666-C30A-49AC-8BB5-1963E93374B6Q36380188-7E21DB43-18A0-4DB9-B819-9197C7FD4444Q36407085-71E15E9F-82CD-4A2D-8289-36F394EF0EF3Q36408216-5F5A5D9B-C9E1-4E6F-ACAB-268A59B48287Q36544872-DE64D7DC-3123-444C-9468-E14D7D8D8438
P2860
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@en
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@nl
type
label
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@en
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@nl
prefLabel
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@en
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@nl
P2093
P1433
P1476
The proteasome inhibitor PS-34 ...... by reducing levels of c-FLIP.
@en
P2093
Alan D Brooks
Arati Raziuddin
Crystal Y Koh
Naoko Seki
Peter J Elliott
Thomas J Sayers
Weihong Ma
William J Murphy
P304
P356
10.1182/BLOOD-2002-09-2975
P407
P577
2003-03-13T00:00:00Z